CompletedNCT01738867
Reward and Brain Responses to Alcohol-Related Medicines in Social Drinkers
About this title
Read the official source — NCT01738867Medication studyAges 18–65United KingdomAddiction
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- CambridgeSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: December 12, 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 56
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United Kingdom
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01738867
- Official title
Show the full official title
A Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Influence of the A118G Polymorphism in the mu Opioid Receptor Gene (OPRM1) on Effects of GSK1521498 and Naltrexone on Physiological and Behavioural Markers of Brain Function in Healthy Social Drinkers
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Cambridge
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including GSK1521498, Naltrexone (NTX) and Placebo.
Who was this study for?
Listed age limits: 18 years to 65 years.
